

Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	26.7	60.0	(34.3-97.4)	Male	13	16.1	81.0	(43.1-138.4)
Female	12	9.7	123.9	(63.9-216.4)	Female	16	12.4	128.6	(73.5-208.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.1	117.4	(42.9-255.6)	Male	1	4.2	nc	(nc-nc)
Female	5	4.0	125.9	(40.6-293.7)	Female	6	2.9	204.9	(74.8-446.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	16	14.2	112.8	(64.4-183.2)
Female	99	94.1	105.2	(85.5-128.0)	Female	7	12.4	56.5	(22.6-116.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	4.0	nc	(nc-nc)	Male	10	10.0	99.6	(47.7-183.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	42	39.4	106.6	(76.8-144.1)	Female	10	10.1	99.1	(47.4-182.3)
Female	32	37.1	86.3	(59.0-121.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	7.9	101.7	(43.8-200.4)
Male	7	6.8	102.7	(41.2-211.7)	Female	2	8.1	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	101	101.0	100.0	(81.4-121.5)
Male	3	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.4	nc	(nc-nc)	Male	14	6.6	212.8	(116.2-357.0)
<u>Kidney and Renal Pelvis</u>					Female	1	3.9	nc	(nc-nc)
Male	18	12.1	149.0	(88.3-235.5)	<u>Testis</u>				
Female	7	7.3	96.2	(38.6-198.3)	Male	3	3.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.2	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	11	10.7	103.0	(51.4-184.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	8.7	nc	(nc-nc)	Female	16	20.1	79.6	(45.5-129.3)
Female	7	6.7	104.9	(42.0-216.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	339	355.2	95.4	(85.5-106.2)
Male	2	5.8	nc	(nc-nc)	Female	325	325.7	99.8	(89.2-111.2)
Female	2	2.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	52	50.1	103.9	(77.6-136.2)					
Female	58	45.7	127.0	(96.4-164.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	58.8	73.2	(52.9-98.6)	Male	26	36.2	71.9	(47.0-105.4)
Female	20	23.1	86.6	(52.9-133.7)	Female	28	31.0	90.3	(60.0-130.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	11.5	95.6	(47.7-171.1)	Male	6	9.2	65.2	(23.8-142.0)
Female	5	9.6	52.3	(16.9-122.1)	Female	8	7.0	114.0	(49.1-224.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.7	nc	(nc-nc)	Male	33	31.9	103.6	(71.3-145.5)
Female	230	219.6	104.7	(91.6-119.2)	Female	32	30.0	106.6	(72.9-150.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	8	9.9	81.0	(34.9-159.6)	Male	31	21.9	141.6	(96.2-200.9)
Female					Female	9	11.0	81.9	(37.4-155.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	74	86.7	85.3	(67.0-107.1)	Female	27	24.0	112.6	(74.2-163.8)
Female	103	88.1	116.9	(95.4-141.8)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	14.9	73.6	(36.7-131.7)	Male	20	17.3	115.8	(70.7-178.9)
Female	6	4.5	132.8	(48.5-289.1)	Female	16	19.2	83.2	(47.5-135.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	6.1	82.6	(26.6-192.8)	Male	211	222.3	94.9	(82.5-108.6)
Female	3	4.7	nc	(nc-nc)					
<u>Kidney and Renal Pelvis</u>					<u>Stomach</u>				
Male	17	26.4	64.3	(37.4-103.0)	Male	15	14.5	103.4	(57.8-170.6)
Female	12	17.3	69.5	(35.9-121.4)	Female	14	9.4	149.6	(81.7-251.1)
<u>Larynx</u>					<u>Testis</u>				
Male	11	9.3	118.6	(59.1-212.2)	Male	7	11.2	62.7	(25.1-129.3)
Female	3	2.7	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	14	19.6	71.5	(39.0-119.9)	Male	5	8.9	56.4	(18.2-131.5)
Female	18	15.9	113.4	(67.2-179.2)	Female	26	27.6	94.3	(61.6-138.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	12.6	103.4	(55.0-176.8)	Female	41	47.1	87.0	(62.4-118.0)
Female	9	4.7	192.3	(87.7-365.0)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	98	110.4	88.8	(72.1-108.2)	Male	714	789.4	90.5	(83.9-97.3)
Female	89	109.4	81.3	(65.3-100.1)	Female	770	776.8	99.1	(92.2-106.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	11.4	61.4	(24.6-126.5)	Male	5	6.7	74.6	(24.0-174.0)
Female	5	4.5	110.2	(35.5-257.3)	Female	4	5.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.1	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
Female	28	41.4	67.6	(44.9-97.7)	Female	5	5.8	86.1	(27.8-201.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	1.7	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	16.8	107.3	(63.5-169.6)	Female	7	4.5	154.2	(61.8-317.8)
Female	11	17.6	62.5	(31.1-111.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.4	nc	(nc-nc)
Male	0	2.9	nc	(nc-nc)	Female	1	3.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	43	43.1	99.8	(72.2-134.4)
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	1	1.9	nc	(nc-nc)
Male	3	5.1	nc	(nc-nc)	<u>Testis</u>				
Female	1	3.3	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	5	4.6	108.3	(34.9-252.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.7	nc	(nc-nc)	Female	9	8.8	101.9	(46.5-193.4)
Female	1	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	135	150.8	89.5	(75.1-106.0)
Male	3	2.4	nc	(nc-nc)	Female	120	148.2	81.0	(67.2-96.9)
Female	2	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	21.3	103.1	(64.6-156.2)					
Female	19	21.1	90.0	(54.2-140.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	26.6	75.2	(45.9-116.1)	Male	18	15.3	118.0	(69.9-186.5)
Female	11	9.8	112.3	(56.0-201.0)	Female	4	12.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.7	105.6	(34.0-246.4)	Male	3	4.1	nc	(nc-nc)
Female	2	3.9	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	10	13.6	73.7	(35.3-135.6)
Female	88	93.8	93.9	(75.3-115.6)	Female	20	12.5	160.3	(97.8-247.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	7	3.9	181.0	(72.5-372.9)	Male	11	9.7	113.7	(56.7-203.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	48	38.9	123.5	(91.1-163.8)	Female	8	10.1	79.1	(34.1-155.8)
Female	40	36.7	108.9	(77.8-148.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	7.8	128.1	(61.3-235.6)
Male	10	6.8	147.7	(70.7-271.6)	Female	8	8.1	98.7	(42.5-194.5)
Female	3	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	115	104.0	110.6	(91.3-132.7)
Male	1	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.5	nc	(nc-nc)	Male	6	6.4	93.2	(34.0-202.9)
<u>Kidney and Renal Pelvis</u>					Female	5	3.8	130.8	(42.1-305.2)
Male	22	11.7	187.3	(117.3-283.6)	<u>Testis</u>				
Female	7	7.4	95.0	(38.1-195.8)	Male	2	2.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	4.2	117.8	(38.0-275.0)	Male	4	3.4	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	5	10.4	48.1	(15.5-112.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	8.3	131.9	(65.7-235.9)	Female	26	20.5	127.0	(82.9-186.0)
Female	3	6.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	405	352.5	114.9	(104.0-126.7)
Male	9	5.6	160.3	(73.1-304.3)	Female	344	326.3	105.4	(94.6-117.2)
Female	4	2.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	65	50.6	128.6	(99.2-163.9)					
Female	64	47.3	135.3	(104.2-172.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.4	111.3	(40.6-242.2)	Male	1	3.3	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	5	2.5	199.7	(64.4-466.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	19	18.3	103.7	(62.4-161.9)	Female	3	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	8.0	87.6	(35.1-180.5)	Female	2	2.0	nc	(nc-nc)
Female	8	6.8	117.3	(50.5-231.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.6	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	14	21.4	65.3	(35.7-109.6)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.3	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.7	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Testis</u>				
Female	5	1.4	357.4	(115.2-834.1)	Male	1	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.8	nc	(nc-nc)	Female	5	3.9	126.6	(40.8-295.5)
Female	1	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	55	73.2	75.2	(56.6-97.9)
Male	0	1.2	nc	(nc-nc)	Female	75	62.7	119.6	(94.1-149.9)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	10.3	58.4	(21.3-127.1)					
Female	16	8.7	183.6	(104.9-298.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	2	3.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	7	11.4	61.5	(24.7-126.8)
Male	1	0.2	nc	(nc-nc)	Female	3	9.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.6	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	2.5	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	4	8.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	5	6.5	76.6	(24.7-178.8)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.1	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	37.3	133.9	(99.4-176.5)	Male	9	21.6	41.6	(19.0-79.0)
Female	19	16.4	116.2	(69.9-181.5)	Female	18	20.3	88.5	(52.4-139.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.6	75.6	(24.4-176.4)	Male	3	5.7	nc	(nc-nc)
Female	5	6.2	81.0	(26.1-189.1)	Female	3	5.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	18	19.3	93.4	(55.4-147.7)
Female	133	144.8	91.9	(76.9-108.9)	Female	24	20.8	115.6	(74.0-172.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	6.4	nc	(nc-nc)	Male	11	12.7	86.7	(43.2-155.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	41	53.9	76.0	(54.5-103.1)	Female	17	15.9	107.1	(62.4-171.5)
Female	52	63.0	82.5	(61.6-108.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	10.7	111.7	(57.7-195.1)
Male	7	9.1	76.8	(30.8-158.3)	Female	10	13.8	72.6	(34.8-133.6)
Female	5	3.2	155.4	(50.1-362.7)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	118	134.3	87.9	(72.7-105.3)
Male	3	3.2	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.7	nc	(nc-nc)	Male	10	9.1	109.4	(52.4-201.2)
<u>Kidney and Renal Pelvis</u>					Female	4	6.8	nc	(nc-nc)
Male	18	15.8	114.1	(67.6-180.3)	<u>Testis</u>				
Female	15	11.7	127.8	(71.5-210.8)	Male	5	5.9	84.8	(27.3-198.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	5.6	89.7	(28.9-209.2)	Male	3	5.0	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	15	17.2	87.3	(48.8-144.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	11.8	50.9	(18.6-110.8)	Female	29	30.5	95.0	(63.6-136.4)
Female	12	10.9	110.0	(56.8-192.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	428	481.4	88.9	(80.7-97.7)
Male	7	7.5	93.6	(37.5-192.8)	Female	484	526.6	91.9	(83.9-100.5)
Female	2	3.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	62	69.1	89.7	(68.8-115.0)					
Female	70	75.7	92.4	(72.0-116.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	16.2	98.6	(56.4-160.2)	Male	12	9.5	125.7	(64.9-219.5)
Female	3	5.5	nc	(nc-nc)	Female	10	7.5	134.0	(64.1-246.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.0	nc	(nc-nc)	Male	5	2.5	196.4	(63.3-458.4)
Female	2	2.4	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	13	8.4	153.8	(81.8-263.1)
Female	67	58.3	114.9	(89.0-145.9)	Female	8	7.2	111.9	(48.2-220.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	2.4	nc	(nc-nc)	Male	3	6.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	24.0	79.2	(47.7-123.7)	Female	11	6.2	178.4	(88.9-319.2)
Female	22	20.8	105.6	(66.2-159.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	4.8	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	67	64.0	104.6	(81.1-132.9)
Male	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	2	2.1	nc	(nc-nc)
Male	3	7.4	nc	(nc-nc)	<u>Testis</u>				
Female	1	4.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.6	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	11	6.5	168.3	(83.9-301.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.2	nc	(nc-nc)	Female	17	12.6	134.5	(78.3-215.3)
Female	6	3.8	158.2	(57.8-344.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	194	217.7	89.1	(77.0-102.6)
Male	3	3.6	nc	(nc-nc)	Female	204	193.8	105.2	(91.3-120.7)
Female	2	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	15	30.9	48.5	(27.1-80.0)					
Female	24	26.9	89.1	(57.1-132.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	20.1	124.6	(80.6-183.9)	Male	12	11.6	103.9	(53.6-181.4)
Female	8	8.1	98.6	(42.5-194.3)	Female	2	9.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.6	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	8	10.3	77.5	(33.4-152.7)
Female	74	71.8	103.0	(80.9-129.4)	Female	12	10.3	116.5	(60.1-203.6)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	3.0	nc	(nc-nc)	Male	7	7.1	98.0	(39.2-201.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	30	29.3	102.5	(69.2-146.4)	Female	6	7.9	76.0	(27.7-165.4)
Female	39	31.7	122.9	(87.4-168.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	5.9	153.6	(70.1-291.7)
Male	8	5.0	160.1	(68.9-315.5)	Female	6	6.9	87.0	(31.8-189.5)
Female	4	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	67	73.2	91.6	(71.0-116.3)
Male	1	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.2	nc	(nc-nc)	Male	5	4.9	101.4	(32.7-236.6)
<u>Kidney and Renal Pelvis</u>					Female	2	3.4	nc	(nc-nc)
Male	6	8.7	69.3	(25.3-150.7)	<u>Testis</u>				
Female	6	5.8	103.2	(37.7-224.7)	Male	2	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.1	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	2	7.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	6.4	156.0	(74.7-286.9)	Female	13	15.2	85.6	(45.6-146.5)
Female	7	5.5	126.4	(50.7-260.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	261	260.1	100.3	(88.5-113.3)
Male	0	4.1	nc	(nc-nc)	Female	256	260.7	98.2	(86.5-111.0)
Female	1	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	40	37.1	107.9	(77.1-146.9)					
Female	33	37.2	88.8	(61.1-124.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	29.2	54.9	(31.3-89.1)	Male	34	17.1	198.8	(137.7-277.9)
Female	8	11.2	71.2	(30.7-140.3)	Female	18	14.7	122.5	(72.5-193.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.4	nc	(nc-nc)	Male	5	4.6	109.3	(35.2-255.0)
Female	2	4.8	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	14	15.2	92.2	(50.3-154.6)
Female	119	109.7	108.4	(89.8-129.8)	Female	8	14.6	54.9	(23.7-108.3)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	4.6	nc	(nc-nc)	Male	16	11.1	144.5	(82.5-234.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	43.1	85.8	(60.4-118.3)	Female	10	12.0	83.7	(40.1-153.9)
Female	51	43.2	118.2	(88.0-155.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	8.6	92.7	(39.9-182.7)
Male	3	7.5	nc	(nc-nc)	Female	11	9.4	117.0	(58.3-209.4)
Female	4	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	138	112.6	122.5	(102.9-144.8)
Male	6	2.1	286.3	(104.6-623.2)	<u>Stomach</u>				
Female	2	2.2	nc	(nc-nc)	Male	3	7.1	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	3	4.6	nc	(nc-nc)
Male	16	13.2	121.6	(69.5-197.5)	<u>Testis</u>				
Female	5	8.5	58.7	(18.9-137.1)	Male	2	3.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.7	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	14	12.9	108.7	(59.4-182.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	9.4	159.2	(89.0-262.6)	Female	12	23.5	51.0	(26.3-89.2)
Female	5	7.9	63.1	(20.3-147.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	371	388.2	95.6	(86.1-105.8)
Male	6	6.4	94.0	(34.3-204.5)	Female	335	381.5	87.8	(78.7-97.7)
Female	2	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	54.9	34.6	(20.8-54.0)					
Female	22	53.1	41.4	(25.9-62.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	4.9	163.7	(70.5-322.6)	Male	3	2.6	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	6	1.9	308.2	(112.5-670.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	14	15.4	90.9	(49.7-152.6)	Female	2	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	7.0	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
Female	4	6.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	26	17.7	146.7	(95.8-215.0)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	0	2.0	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	1.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.0	nc	(nc-nc)	Female	6	3.4	177.6	(64.8-386.5)
Female	1	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	5	9.0	55.5	(17.9-129.4)	Male	66	61.3	107.6	(83.2-136.9)
Female	8	8.0	100.6	(43.3-198.2)	Female	56	53.6	104.5	(78.9-135.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	3.6	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	8	12.2	65.8	(28.3-129.7)
Male	0	0.2	nc	(nc-nc)	Female	8	9.8	81.7	(35.2-160.9)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.5	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.0	99.1	(31.9-231.2)	Male	3	2.8	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	6	2.3	262.8	(96.0-572.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	16	16.8	95.1	(54.3-154.5)	Female	2	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	7.3	68.4	(22.0-159.5)	Female	1	1.9	nc	(nc-nc)
Female	13	6.7	194.3	(103.3-332.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	1.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	18	18.4	97.6	(57.8-154.2)
Male	2	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.7	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.6	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	65	65.3	99.6	(76.9-126.9)
Male	1	1.0	nc	(nc-nc)	Female	59	59.4	99.4	(75.6-128.2)
Female	1	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	9.4	148.4	(81.0-248.9)					
Female	7	8.5	82.3	(33.0-169.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.9	67.2	(24.5-146.2)	Male	2	5.5	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	5	4.9	102.2	(32.9-238.4)
Female	30	28.2	106.5	(71.8-152.0)	Female	5	3.8	130.7	(42.1-305.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	1.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	13.2	75.7	(36.2-139.2)	Female	5	3.0	164.3	(52.9-383.4)
Female	7	11.6	60.6	(24.3-124.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.6	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	29	32.9	88.3	(59.1-126.8)
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	5	4.0	124.4	(40.1-290.3)	<u>Testis</u>				
Female	3	2.2	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.0	nc	(nc-nc)	Female	8	6.0	134.3	(57.8-264.7)
Female	4	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	97	119.1	81.5	(66.1-99.4)
Male	0	1.9	nc	(nc-nc)	Female	100	98.9	101.1	(82.2-122.9)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	16.6	78.2	(41.6-133.8)					
Female	15	14.1	106.2	(59.4-175.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.1	88.1	(37.9-173.6)	Male	4	5.1	nc	(nc-nc)
Female	7	3.5	197.5	(79.1-406.9)	Female	4	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.6	130.9	(47.8-284.9)
Female	21	31.9	65.8	(40.7-100.7)	Female	6	4.5	134.2	(49.0-292.1)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	13.2	75.8	(36.3-139.4)	Female	2	3.5	nc	(nc-nc)
Female	12	13.7	87.6	(45.2-153.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	2.6	188.7	(60.8-440.4)
Male	3	2.3	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	31	33.7	91.9	(62.4-130.4)
Male	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	1.5	nc	(nc-nc)
Male	5	3.9	128.6	(41.4-300.0)	<u>Testis</u>				
Female	2	2.6	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	1.4	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	5	3.3	150.4	(48.5-351.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.8	nc	(nc-nc)	Female	5	6.9	72.9	(23.5-170.0)
Female	1	2.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	115	117.5	97.8	(80.8-117.5)
Male	2	1.9	nc	(nc-nc)	Female	98	114.1	85.9	(69.7-104.6)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	16.9	118.5	(72.3-183.0)					
Female	19	16.5	115.0	(69.2-179.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	5.1	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	0	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.1	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	10	20.5	48.7	(23.3-89.5)	Female	0	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	7.3	122.7	(56.0-232.9)	Female	2	2.3	nc	(nc-nc)
Female	9	10.5	85.4	(39.0-162.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	19	17.8	106.6	(64.2-166.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney and Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.1	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.8	nc	(nc-nc)	Male	60	63.9	93.9	(71.6-120.8)
Female	0	0.2	nc	(nc-nc)	Female	51	77.6	65.7	(48.9-86.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	2	1.7	nc	(nc-nc)	Male	60	63.9	93.9	(71.6-120.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.0	nc	(nc-nc)	Female	51	77.6	65.7	(48.9-86.4)
Female	1	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	9	8.9	100.6	(45.9-190.9)	Male	60	63.9	93.9	(71.6-120.8)
Female	5	10.8	46.4	(14.9-108.2)	Female	51	77.6	65.7	(48.9-86.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.8	130.7	(42.1-305.0)	Male	2	2.7	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	7	2.1	333.8	(133.7-687.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	10	15.7	63.7	(30.5-117.1)	Female	2	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	6.0	82.9	(26.7-193.5)	Female	2	1.6	nc	(nc-nc)
Female	8	4.8	166.0	(71.5-327.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	25	16.5	151.2	(97.8-223.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	1	2.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.7	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	1.4	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.0	nc	(nc-nc)	Female	1	3.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	3	7.4	nc	(nc-nc)	Male	51	56.2	90.8	(67.6-119.3)
Female	7	6.3	111.3	(44.6-229.4)	Female	50	49.3	101.3	(75.2-133.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	38	33.7	112.9	(79.9-155.0)	Male	15	19.5	76.8	(43.0-126.7)
Female	10	12.5	79.7	(38.1-146.5)	Female	14	15.8	88.8	(48.5-149.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.1	147.6	(67.3-280.2)	Male	2	5.2	nc	(nc-nc)
Female	2	5.0	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	14	17.4	80.6	(44.0-135.2)
Female	127	117.7	107.9	(90.0-128.4)	Female	15	16.1	93.3	(52.2-153.8)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	4.9	nc	(nc-nc)	Male	10	12.1	82.7	(39.6-152.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	46	49.1	93.7	(68.6-124.9)	Female	14	12.8	109.4	(59.8-183.6)
Female	44	47.9	91.8	(66.7-123.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	9.8	91.6	(41.8-173.9)
Male	9	8.5	106.5	(48.6-202.2)	Female	10	10.5	95.4	(45.7-175.4)
Female	5	2.5	203.2	(65.5-474.1)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	126	126.5	99.6	(83.0-118.6)
Male	3	2.6	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.0	nc	(nc-nc)	Male	10	8.2	121.6	(58.2-223.7)
<u>Kidney and Renal Pelvis</u>					Female	5	5.1	98.6	(31.8-230.1)
Male	18	14.7	122.5	(72.5-193.5)	<u>Testis</u>				
Female	7	9.3	75.0	(30.1-154.6)	Male	4	4.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	5.2	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	11	13.3	82.7	(41.2-148.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	10.7	102.6	(51.2-183.6)	Female	23	25.3	91.0	(57.7-136.5)
Female	2	8.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	429	441.5	97.2	(88.2-106.8)
Male	2	7.0	nc	(nc-nc)	Female	400	415.3	96.3	(87.1-106.2)
Female	4	2.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	64	63.0	101.6	(78.2-129.7)					
Female	53	59.6	88.9	(66.6-116.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	7	7.1	98.7	(39.5-203.4)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	7.9	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	18	27.7	65.1	(38.5-102.8)
Male	0	0.5	nc	(nc-nc)	Female	20	23.8	84.1	(51.3-129.9)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	4.0	nc	(nc-nc)					
Female	5	3.4	147.1	(47.4-343.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.7	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	12	10.5	114.4	(59.0-199.8)	Female	0	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	4.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	5	3.3	151.0	(48.7-352.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	20	10.8	184.5	(112.6-284.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney and Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.3	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Male	42	37.6	111.8	(80.6-151.1)
Female	0	0.1	nc	(nc-nc)	Female	31	33.3	93.1	(63.3-132.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	2	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	2	5.1	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	4	4.3	nc	(nc-nc)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	16.6	114.4	(68.9-178.7)	Male	11	10.9	100.9	(50.3-180.6)
Female	3	6.6	nc	(nc-nc)	Female	14	9.3	149.8	(81.8-251.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.6	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	12	9.5	126.0	(65.0-220.1)
Female	63	66.3	95.1	(73.1-121.6)	Female	7	8.7	80.4	(32.2-165.7)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	3.1	nc	(nc-nc)	Male	4	6.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	25.1	75.6	(45.5-118.1)	Female	10	7.1	141.4	(67.7-260.1)
Female	22	26.3	83.6	(52.4-126.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	5.0	141.0	(56.5-290.6)
Male	3	4.3	nc	(nc-nc)	Female	1	5.6	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	61	62.5	97.7	(74.7-125.5)
Male	1	1.7	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.2	nc	(nc-nc)	Male	6	4.2	143.5	(52.4-312.4)
<u>Kidney and Renal Pelvis</u>					Female	1	2.9	nc	(nc-nc)
Male	9	7.9	113.9	(52.0-216.2)	<u>Testis</u>				
Female	1	5.0	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.7	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	4	8.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	5.9	153.8	(70.2-292.0)	Female	12	13.5	88.9	(45.9-155.3)
Female	1	4.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	214	227.2	94.2	(82.0-107.7)
Male	4	3.8	nc	(nc-nc)	Female	192	228.8	83.9	(72.5-96.7)
Female	2	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	30.7	68.4	(42.3-104.6)					
Female	25	29.9	83.6	(54.1-123.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	42.0	111.9	(82.2-148.7)	Male	19	25.2	75.4	(45.4-117.8)
Female	18	16.1	111.5	(66.1-176.3)	Female	19	21.1	90.2	(54.3-140.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	8.1	74.1	(27.0-161.2)	Male	5	6.6	76.1	(24.5-177.6)
Female	4	6.7	nc	(nc-nc)	Female	2	4.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.2	nc	(nc-nc)	Male	18	22.4	80.4	(47.6-127.0)
Female	153	153.9	99.4	(84.3-116.4)	Female	27	20.9	129.2	(85.1-188.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	7	6.7	105.2	(42.2-216.8)	Male	12	15.8	76.1	(39.3-132.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	62	62.0	100.0	(76.6-128.2)	Female	19	16.8	113.2	(68.1-176.8)
Female	58	62.2	93.3	(70.8-120.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	13	12.4	105.1	(55.9-179.7)
Male	11	10.7	102.9	(51.3-184.1)	Female	11	13.5	81.3	(40.5-145.5)
Female	5	3.2	158.2	(51.0-369.3)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	136	157.1	86.6	(72.6-102.4)
Male	1	3.7	nc	(nc-nc)	<u>Stomach</u>				
Female	2	3.0	nc	(nc-nc)	Male	12	10.4	115.8	(59.8-202.4)
<u>Kidney and Renal Pelvis</u>					Female	4	6.6	nc	(nc-nc)
Male	28	18.7	149.4	(99.2-215.9)	<u>Testis</u>				
Female	8	12.1	66.2	(28.5-130.5)	Male	5	6.2	80.3	(25.9-187.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	6.6	75.6	(24.4-176.5)	Male	1	5.9	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	14	18.4	76.3	(41.7-128.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	13.9	71.9	(34.4-132.3)	Female	35	32.7	107.0	(74.5-148.9)
Female	4	11.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	529	557.6	94.9	(87.0-103.3)
Male	5	9.1	55.2	(17.8-128.9)	Female	524	541.7	96.7	(88.6-105.4)
Female	3	3.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	101	78.2	129.1	(105.1-156.9)					
Female	79	75.9	104.1	(82.4-129.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	15.2	118.7	(70.3-187.5)	Male	14	11.3	124.2	(67.8-208.4)
Female	7	5.5	128.3	(51.4-264.3)	Female	13	9.6	134.9	(71.8-230.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.0	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	10	9.6	104.0	(49.8-191.3)
Female	75	68.7	109.1	(85.8-136.8)	Female	9	7.7	116.6	(53.2-221.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	5	3.5	142.5	(45.9-332.7)	Male	2	7.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	31	24.2	127.8	(86.8-181.5)	Female	15	7.1	212.2	(118.7-349.9)
Female	23	21.0	109.4	(69.3-164.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	4.8	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	61	66.4	91.9	(70.3-118.1)
Male	0	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.3	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	2	2.2	nc	(nc-nc)
Male	9	8.5	105.7	(48.2-200.7)	<u>Testis</u>				
Female	3	4.7	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.8	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	11	9.8	112.6	(56.1-201.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.8	85.6	(27.6-199.9)	Female	11	14.2	77.2	(38.5-138.2)
Female	3	4.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	223	229.9	97.0	(84.7-110.6)
Male	3	4.1	nc	(nc-nc)	Female	231	217.2	106.4	(93.1-121.0)
Female	1	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	31	30.0	103.4	(70.2-146.7)					
Female	28	26.8	104.6	(69.5-151.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.5	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	7	5.9	117.8	(47.2-242.6)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	8	6.4	125.3	(53.9-246.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	0	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	0.4	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	3	2.9	nc	(nc-nc)	Female	21	21.5	97.6	(60.4-149.1)
Female	0	2.3	nc	(nc-nc)	Female	13	18.5	70.4	(37.5-120.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	7.0	113.6	(48.9-223.8)	Male	2	4.6	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	25	26.6	94.2	(60.9-139.0)	Female	1	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	10.8	138.7	(77.6-228.7)	Female	3	2.8	nc	(nc-nc)
Female	8	8.9	90.3	(38.9-177.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	1.9	nc	(nc-nc)	Male	28	28.1	99.5	(66.1-143.8)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.6	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney and Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.5	nc	(nc-nc)	Female	12	5.6	216.0	(111.5-377.3)
Female	3	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Male	91	98.6	92.3	(74.3-113.3)
Female	0	0.3	nc	(nc-nc)	Female	90	86.4	104.2	(83.8-128.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	9	13.4	67.1	(30.6-127.3)	<u>All Sites / Types</u>				
Female	12	11.4	105.5	(54.4-184.2)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	16.5	54.5	(24.9-103.5)	Male	14	9.2	152.8	(83.5-256.4)
Female	5	5.3	93.5	(30.1-218.2)	Female	10	6.6	151.0	(72.3-277.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	6	2.1	279.5	(102.1-608.3)	Female	0	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	9	8.2	109.6	(50.0-208.1)
Female	57	51.5	110.8	(83.9-143.5)	Female	7	6.8	102.8	(41.2-211.8)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	2.1	nc	(nc-nc)	Male	1	5.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	24.0	79.2	(47.6-123.6)	Female	4	5.6	nc	(nc-nc)
Female	14	20.8	67.2	(36.7-112.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	4.8	nc	(nc-nc)
Male	3	4.1	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	79	61.7	128.1	(101.4-159.7)
Male	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	3	2.2	nc	(nc-nc)
Male	8	7.1	113.4	(48.8-223.5)	<u>Testis</u>				
Female	5	4.0	125.6	(40.5-293.2)	Male	1	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	2.6	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	17	5.5	307.6	(179.1-492.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	5.1	118.1	(43.1-257.0)	Female	9	11.1	81.3	(37.1-154.4)
Female	4	3.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	202	212.5	95.1	(82.4-109.1)
Male	4	3.4	nc	(nc-nc)	Female	180	178.7	100.7	(86.6-116.6)
Female	1	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	30.4	46.1	(25.2-77.3)					
Female	15	24.8	60.4	(33.8-99.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	18.3	152.6	(101.4-220.5)	Male	11	11.0	99.7	(49.7-178.4)
Female	7	6.2	113.0	(45.3-232.9)	Female	6	8.4	71.4	(26.1-155.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.4	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	5	1.9	261.5	(84.3-610.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	8	9.7	82.5	(35.5-162.6)
Female	85	64.2	132.5	(105.8-163.8)	Female	8	8.1	99.1	(42.7-195.3)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	8	7.3	109.8	(47.3-216.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	27.4	65.8	(39.0-104.0)	Female	8	6.9	116.7	(50.3-230.0)
Female	20	23.3	85.9	(52.4-132.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	5.5	nc	(nc-nc)
Male	3	4.9	nc	(nc-nc)	Female	5	5.1	98.1	(31.6-228.8)
Female	0	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	73	74.0	98.7	(77.3-124.1)
Male	3	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.0	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	2	2.4	nc	(nc-nc)
Male	8	8.5	93.9	(40.4-185.0)	<u>Testis</u>				
Female	5	4.9	103.0	(33.2-240.3)	Male	4	2.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.1	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	13	7.4	176.2	(93.7-301.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	5.8	154.3	(70.4-292.8)	Female	20	14.1	141.6	(86.5-218.8)
Female	4	4.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	256	249.8	102.5	(90.3-115.8)
Male	2	4.1	nc	(nc-nc)	Female	250	216.0	115.7	(101.8-131.0)
Female	2	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	44	35.1	125.3	(91.0-168.2)					
Female	29	30.4	95.5	(64.0-137.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	20.5	92.8	(55.9-145.0)	Male	10	11.1	90.2	(43.2-165.9)
Female	5	7.6	66.0	(21.3-154.1)	Female	21	8.6	244.2	(151.1-373.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.4	178.9	(65.3-389.5)	Male	1	3.1	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	5	2.3	217.8	(70.2-508.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	11	10.0	109.9	(54.8-196.7)
Female	68	66.7	101.9	(79.2-129.2)	Female	9	9.5	95.0	(43.4-180.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	7	6.8	103.5	(41.4-213.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	29.3	85.4	(55.2-126.0)	Female	5	7.3	68.7	(22.1-160.3)
Female	37	29.7	124.7	(87.8-171.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	5.9	nc	(nc-nc)
Male	2	4.9	nc	(nc-nc)	Female	8	6.4	124.2	(53.5-244.6)
Female	1	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	79	71.7	110.2	(87.2-137.3)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	5.0	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	1	3.2	nc	(nc-nc)
Male	9	8.3	108.1	(49.3-205.2)	<u>Testis</u>				
Female	7	5.4	129.9	(52.0-267.6)	Male	3	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.0	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	7	6.7	103.8	(41.6-213.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	6.3	111.6	(44.7-230.0)	Female	11	14.1	78.1	(38.9-139.7)
Female	6	5.1	117.5	(42.9-255.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	237	255.3	92.8	(81.4-105.4)
Male	2	4.0	nc	(nc-nc)	Female	249	240.7	103.5	(91.0-117.1)
Female	0	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	27	37.0	73.0	(48.1-106.3)					
Female	28	34.5	81.1	(53.9-117.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	75	61.1	122.8	(96.6-154.0)	Male	43	36.3	118.5	(85.8-159.7)
Female	22	25.0	88.1	(55.2-133.4)	Female	42	31.9	131.6	(94.8-177.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	11.5	104.4	(53.9-182.4)	Male	11	9.5	115.3	(57.5-206.4)
Female	6	10.0	60.1	(21.9-130.7)	Female	3	7.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.7	nc	(nc-nc)	Male	34	32.1	106.0	(73.4-148.1)
Female	242	238.3	101.6	(89.2-115.2)	Female	23	32.0	71.9	(45.6-108.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	9	10.1	88.7	(40.5-168.4)	Male	27	22.8	118.6	(78.2-172.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	90	89.9	100.1	(80.5-123.1)	Female	30	25.7	116.6	(78.7-166.5)
Female	86	94.7	90.8	(72.6-112.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	18	18.0	100.1	(59.3-158.3)
Male	19	15.7	121.3	(73.0-189.5)	Female	17	20.7	82.0	(47.7-131.2)
Female	2	4.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	204	236.5	86.3	(74.8-99.0)
Male	3	4.9	nc	(nc-nc)	<u>Stomach</u>				
Female	2	3.9	nc	(nc-nc)	Male	8	14.9	53.7	(23.1-105.8)
<u>Kidney and Renal Pelvis</u>					Female	11	10.0	110.1	(54.9-197.1)
Male	36	27.5	130.8	(91.6-181.0)	<u>Testis</u>				
Female	27	18.7	144.2	(95.0-209.8)	Male	9	8.3	108.0	(49.3-205.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	9.8	61.5	(22.5-133.9)	Male	8	8.4	95.0	(40.9-187.2)
Female	4	2.9	nc	(nc-nc)	Female	35	27.3	128.2	(89.3-178.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	19.7	86.3	(50.2-138.2)	Female	50	51.2	97.7	(72.5-128.8)
Female	16	16.8	95.2	(54.4-154.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	837	816.5	102.5	(95.7-109.7)
Male	9	13.2	68.4	(31.2-129.8)	Female	839	832.8	100.7	(94.0-107.8)
Female	6	5.0	119.3	(43.6-259.6)					
<u>Lung and Bronchus</u>									
Male	132	116.0	113.7	(95.2-134.9)					
Female	149	119.1	125.1	(105.8-146.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.9	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	6.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	2.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	7	7.1	98.1	(39.3-202.2)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	2	0.2	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	24	25.2	95.1	(60.9-141.5)
Male	0	0.4	nc	(nc-nc)	Female	12	21.2	56.6	(29.2-98.9)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	3.5	nc	(nc-nc)					
Female	1	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	11.8	126.9	(71.0-209.3)	Male	6	7.9	75.6	(27.6-164.6)
Female	5	4.4	112.6	(36.3-262.8)	Female	6	6.9	86.9	(31.7-189.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.7	224.1	(81.8-487.8)	Male	2	1.9	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	6.9	145.1	(69.4-266.8)
Female	45	48.9	92.1	(67.2-123.2)	Female	6	6.0	99.5	(36.3-216.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	2.4	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	18.2	88.1	(50.3-143.1)	Female	3	5.2	nc	(nc-nc)
Female	17	16.8	101.1	(58.8-161.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.6	138.8	(44.7-324.0)
Male	9	3.2	278.5	(127.1-528.6)	Female	4	3.6	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	35	48.9	71.6	(49.9-99.6)
Male	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.0	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	1.7	nc	(nc-nc)
Male	6	6.0	100.8	(36.8-219.5)	<u>Testis</u>				
Female	4	3.6	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.1	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	7	6.6	105.7	(42.3-217.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.2	nc	(nc-nc)	Female	5	10.4	48.1	(15.5-112.2)
Female	5	3.3	152.4	(49.1-355.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	172	169.3	101.6	(87.0-118.0)
Male	1	2.9	nc	(nc-nc)	Female	159	162.9	97.6	(83.0-114.0)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	26	22.9	113.8	(74.3-166.7)					
Female	23	21.7	105.8	(67.0-158.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	18.5	70.3	(37.4-120.2)	Male	10	10.6	94.4	(45.2-173.7)
Female	6	6.7	89.2	(32.6-194.2)	Female	9	8.3	108.8	(49.6-206.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.3	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	15	9.4	158.8	(88.8-261.9)
Female	82	64.5	127.2	(101.2-157.9)	Female	16	8.5	187.4	(107.1-304.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	3	6.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	27.2	62.5	(36.4-100.1)	Female	9	6.9	129.8	(59.2-246.4)
Female	35	25.9	135.3	(94.2-188.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	5.5	nc	(nc-nc)
Male	2	4.7	nc	(nc-nc)	Female	6	5.6	106.3	(38.8-231.3)
Female	2	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	85	71.1	119.5	(95.5-147.8)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.9	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	2	2.7	nc	(nc-nc)
Male	4	8.2	nc	(nc-nc)	<u>Testis</u>				
Female	3	5.0	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.9	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	5	6.8	73.1	(23.6-170.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.8	86.4	(27.8-201.6)	Female	12	13.8	86.8	(44.8-151.6)
Female	2	4.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	196	243.8	80.4	(69.5-92.5)
Male	2	4.0	nc	(nc-nc)	Female	234	223.5	104.7	(91.7-119.0)
Female	4	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	34.9	40.1	(21.9-67.3)					
Female	14	31.7	44.2	(24.1-74.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	3.1	195.0	(71.2-424.4)	Male	1	1.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	17	10.6	160.6	(93.5-257.2)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	4.6	218.3	(104.5-401.5)	Female	0	1.1	nc	(nc-nc)
Female	1	3.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.9	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	11	11.7	94.1	(46.9-168.4)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Testis</u>				
Female	3	0.8	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.0	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	49	40.8	120.1	(88.8-158.7)
Male	1	0.7	nc	(nc-nc)	Female	36	34.5	104.4	(73.1-144.6)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	5.7	87.9	(28.3-205.1)					
Female	3	4.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	10.7	111.7	(57.6-195.1)	Male	7	5.7	123.6	(49.5-254.6)
Female	0	4.7	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.2	96.5	(31.1-225.3)
Female	39	37.0	105.5	(75.0-144.2)	Female	7	5.7	121.9	(48.8-251.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	15.2	72.3	(36.0-129.3)	Female	2	4.2	nc	(nc-nc)
Female	17	18.6	91.6	(53.3-146.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	2.5	nc	(nc-nc)	Male	69	37.0	186.7	(145.3-236.3)
Female	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney and Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	4.2	nc	(nc-nc)	Female	10	7.9	126.9	(60.8-233.4)
Female	1	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.5	nc	(nc-nc)	Male	151	132.7	113.8	(96.4-133.4)
Female	2	0.5	nc	(nc-nc)	Female	129	141.0	91.5	(76.4-108.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	3.3	212.6	(85.2-438.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.1	163.3	(52.6-381.0)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	19.3	72.6	(39.6-121.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	20.5	92.7	(55.8-144.8)	<u>Uteri Corpus and Uterus, NOS</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	19.5	82.2	(46.9-133.5)	Male	12	12.7	94.1	(48.6-164.4)
Female	5	7.3	68.2	(22.0-159.2)	Female	6	10.7	55.9	(20.4-121.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.3	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	7	11.1	63.1	(25.3-130.0)
Female	94	77.5	121.3	(98.0-148.5)	Female	10	9.7	103.0	(49.3-189.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	3.7	nc	(nc-nc)	Male	8	8.2	97.5	(42.0-192.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	34	29.6	114.9	(79.5-160.5)	Female	9	8.2	109.8	(50.1-208.4)
Female	18	27.8	64.7	(38.3-102.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	5.9	nc	(nc-nc)
Male	5	5.3	94.9	(30.6-221.4)	Female	7	6.0	116.0	(46.5-239.1)
Female	1	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	98	80.1	122.4	(99.4-149.2)
Male	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.4	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	3	2.9	nc	(nc-nc)
Male	9	9.6	93.3	(42.6-177.1)	<u>Testis</u>				
Female	5	5.8	86.5	(27.9-201.8)	Male	4	3.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.3	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	12	10.0	119.8	(61.8-209.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	6.8	102.7	(41.1-211.5)	Female	25	16.5	151.6	(98.1-223.8)
Female	8	5.3	149.7	(64.5-295.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	292	275.4	106.0	(94.2-118.9)
Male	1	4.6	nc	(nc-nc)	Female	276	261.0	105.7	(93.6-119.0)
Female	1	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	42	37.7	111.3	(80.2-150.4)					
Female	43	35.3	121.8	(88.2-164.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.6	81.7	(32.7-168.4)	Male	2	5.6	nc	(nc-nc)
Female	5	3.1	159.4	(51.4-371.9)	Female	3	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.9	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
Female	29	33.0	87.9	(58.9-126.2)	Female	1	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	5	3.6	138.9	(44.8-324.1)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	12	13.0	92.0	(47.5-160.8)	<u>Ovary</u>				
Female	11	11.9	92.2	(46.0-165.0)	Female	8	3.5	227.2	(97.8-447.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.3	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	31	34.7	89.3	(60.6-126.7)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	2.1	nc	(nc-nc)
Male	5	4.2	117.8	(38.0-274.9)	Female	1	1.3	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.5	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	4.4	nc	(nc-nc)
Male	5	3.0	164.7	(53.1-384.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.3	nc	(nc-nc)	Female	5	7.0	71.6	(23.1-167.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.0	nc	(nc-nc)	Male	117	120.8	96.8	(80.1-116.0)
Female	0	0.6	nc	(nc-nc)	Female	110	112.0	98.2	(80.7-118.4)
<u>Lung and Bronchus</u>									
Male	17	16.4	103.5	(60.2-165.7)					
Female	25	15.1	165.2	(106.9-243.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	27.3	91.7	(59.3-135.4)	Male	22	15.6	141.3	(88.5-213.9)
Female	5	10.8	46.2	(14.9-107.7)	Female	16	13.0	123.4	(70.5-200.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	4.8	249.1	(128.5-435.1)	Male	3	4.2	nc	(nc-nc)
Female	6	4.1	144.9	(52.9-315.5)	Female	5	3.3	152.3	(49.1-355.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.8	nc	(nc-nc)	Male	15	13.9	108.2	(60.5-178.5)
Female	112	99.5	112.6	(92.7-135.4)	Female	14	13.7	102.3	(55.9-171.7)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	4.0	nc	(nc-nc)	Male	5	9.8	50.8	(16.4-118.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	39.8	60.3	(38.6-89.8)	Female	9	10.8	83.4	(38.1-158.4)
Female	38	42.5	89.5	(63.3-122.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	8.0	62.5	(20.2-146.0)
Male	2	6.9	nc	(nc-nc)	Female	6	9.2	65.3	(23.9-142.2)
Female	2	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	122	102.7	118.8	(98.7-141.9)
Male	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.4	nc	(nc-nc)	Male	3	6.6	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	3	4.6	nc	(nc-nc)
Male	14	11.9	117.7	(64.3-197.5)	<u>Testis</u>				
Female	8	7.8	102.0	(43.9-201.0)	Male	2	2.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	4.3	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	13	10.5	123.4	(65.7-211.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	8.6	105.2	(48.0-199.7)	Female	23	21.2	108.6	(68.8-163.0)
Female	7	7.4	95.1	(38.1-195.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	337	355.5	94.8	(85.0-105.5)
Male	4	5.7	nc	(nc-nc)	Female	339	352.7	96.1	(86.2-106.9)
Female	2	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	33	50.8	64.9	(44.7-91.2)					
Female	36	49.6	72.6	(50.9-100.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	3	3.7	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	7	12.7	55.0	(22.0-113.3)
Male	0	0.2	nc	(nc-nc)	Female	8	10.7	74.8	(32.2-147.4)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.7	nc	(nc-nc)					
Female	1	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	20.9	114.6	(73.4-170.5)	Male	19	12.4	153.5	(92.4-239.7)
Female	10	8.5	118.2	(56.6-217.4)	Female	14	10.7	130.5	(71.3-218.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	3.8	184.0	(73.7-379.1)	Male	3	3.3	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	5	2.6	194.0	(62.5-452.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	7	10.9	64.0	(25.6-131.8)
Female	77	78.3	98.3	(77.6-122.9)	Female	11	10.8	101.7	(50.7-182.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	3.4	nc	(nc-nc)	Male	5	7.6	65.6	(21.1-153.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	34	30.7	110.6	(76.6-154.6)	Female	16	8.5	188.4	(107.6-306.0)
Female	39	32.6	119.5	(85.0-163.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	6.1	nc	(nc-nc)
Male	7	5.3	132.8	(53.2-273.6)	Female	7	7.1	98.5	(39.4-202.9)
Female	0	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	85	78.0	109.0	(87.0-134.7)
Male	1	1.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.3	nc	(nc-nc)	Male	1	5.1	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	4	3.5	nc	(nc-nc)
Male	21	9.2	227.4	(140.7-347.6)	<u>Testis</u>				
Female	6	6.2	96.6	(35.3-210.2)	Male	3	2.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.3	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	9	9.2	98.2	(44.8-186.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	6.7	135.0	(61.6-256.4)	Female	17	16.5	103.0	(60.0-164.9)
Female	4	5.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	307	275.1	111.6	(99.5-124.8)
Male	4	4.4	nc	(nc-nc)	Female	306	278.3	109.9	(98.0-123.0)
Female	1	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	47	39.0	120.6	(88.6-160.4)					
Female	55	39.4	139.4	(105.0-181.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	42.9	93.2	(66.6-127.0)	Male	37	25.6	144.7	(101.9-199.5)
Female	20	16.4	121.9	(74.4-188.3)	Female	19	21.1	89.9	(54.1-140.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	8.1	74.5	(27.2-162.1)	Male	9	6.7	134.6	(61.4-255.6)
Female	9	6.6	136.4	(62.2-259.0)	Female	7	4.9	141.5	(56.7-291.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.2	nc	(nc-nc)	Male	30	22.6	133.0	(89.7-189.9)
Female	169	155.7	108.5	(92.8-126.2)	Female	22	20.9	105.2	(65.9-159.3)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	5	6.7	74.1	(23.9-172.9)	Male	15	15.7	95.7	(53.5-157.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	68	62.9	108.0	(83.9-137.0)	Female	12	16.8	71.5	(36.9-125.0)
Female	65	61.4	105.9	(81.7-134.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	20	12.6	159.2	(97.2-245.9)
Male	12	10.9	109.9	(56.7-192.0)	Female	18	13.5	132.9	(78.7-210.0)
Female	1	3.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	160	166.0	96.4	(82.0-112.5)
Male	3	3.6	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.7	nc	(nc-nc)	Male	9	10.5	86.1	(39.3-163.4)
<u>Kidney and Renal Pelvis</u>					Female	5	6.4	77.7	(25.0-181.3)
Male	24	19.3	124.5	(79.8-185.3)	<u>Testis</u>				
Female	6	12.3	48.9	(17.9-106.4)	Male	3	6.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	6.8	103.0	(41.2-212.1)	Male	7	6.0	116.3	(46.6-239.7)
Female	1	1.9	nc	(nc-nc)	Female	26	18.3	142.4	(93.0-208.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	13.8	130.5	(77.3-206.2)	Female	31	33.6	92.4	(62.7-131.1)
Female	6	11.0	54.6	(19.9-118.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	585	573.6	102.0	(93.9-110.6)
Male	5	9.1	54.8	(17.6-127.8)	Female	566	545.7	103.7	(95.3-112.6)
Female	3	3.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	79	81.9	96.5	(76.4-120.3)					
Female	91	78.9	115.3	(92.8-141.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	162	171.0	94.7	(80.7-110.5)	Male	62	101.9	60.9	(46.7-78.0)
Female	64	69.9	91.5	(70.5-116.9)	Female	47	90.6	51.9	(38.1-69.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	20	33.2	60.3	(36.8-93.1)	Male	27	26.4	102.1	(67.3-148.5)
Female	26	29.1	89.5	(58.4-131.1)	Female	13	21.2	61.4	(32.7-105.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	4.8	nc	(nc-nc)	Male	87	90.9	95.7	(76.6-118.0)
Female	553	638.3	86.6	(79.6-94.2)	Female	95	90.4	105.0	(85.0-128.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	38	28.5	133.4	(94.4-183.1)	Male	52	60.9	85.4	(63.8-112.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	238	249.5	95.4	(83.7-108.3)	Female	73	70.2	103.9	(81.5-130.7)
Female	250	271.7	92.0	(81.0-104.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	61	49.7	122.7	(93.9-157.6)
Male	42	42.3	99.3	(71.6-134.2)	Female	57	59.0	96.6	(73.1-125.1)
Female	16	13.7	116.7	(66.7-189.5)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	453	618.6	73.2	(66.6-80.3)
Male	12	16.4	73.0	(37.7-127.6)	<u>Stomach</u>				
Female	11	13.7	80.2	(40.0-143.5)	Male	43	42.2	101.9	(73.7-137.2)
<u>Kidney and Renal Pelvis</u>					Female	32	29.4	108.8	(74.4-153.6)
Male	65	74.2	87.6	(67.6-111.7)	<u>Testis</u>				
Female	54	51.1	105.7	(79.4-137.9)	Male	26	28.7	90.6	(59.2-132.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	31	26.0	119.3	(81.0-169.3)	Male	23	23.9	96.2	(61.0-144.4)
Female	8	7.7	104.1	(44.8-205.2)	Female	49	78.9	62.1	(45.9-82.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	62	57.4	108.0	(82.8-138.4)	Female	146	134.2	108.8	(91.9-127.9)
Female	40	49.5	80.8	(57.7-110.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	2012	2237.9	89.9	(86.0-93.9)
Male	46	35.4	130.0	(95.2-173.4)	Female	2126	2304.6	92.3	(88.4-96.3)
Female	21	14.3	147.2	(91.1-225.1)					
<u>Lung and Bronchus</u>									
Male	342	314.7	108.7	(97.5-120.8)					
Female	316	322.8	97.9	(87.4-109.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	1.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	7	5.4	129.4	(51.9-266.7)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	6	6.3	95.0	(34.7-206.8)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	17	21.3	79.7	(46.4-127.6)
Male	0	0.4	nc	(nc-nc)	Female	14	17.4	80.6	(44.0-135.2)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	3.0	nc	(nc-nc)					
Female	3	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	10.1	88.8	(40.5-168.7)	Male	14	6.7	208.2	(113.7-349.4)
Female	7	4.1	168.9	(67.7-348.1)	Female	7	5.7	122.2	(49.0-251.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.2	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.8	137.1	(59.1-270.2)
Female	34	42.0	81.0	(56.1-113.2)	Female	4	5.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	15.5	141.9	(88.9-214.9)	Female	7	4.5	157.2	(63.0-323.9)
Female	18	16.4	109.6	(64.9-173.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.1	163.0	(52.5-380.3)
Male	3	2.7	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	31	39.5	78.5	(53.3-111.4)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	2	1.8	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	<u>Testis</u>				
Female	4	3.1	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	5	5.2	96.7	(31.2-225.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.5	nc	(nc-nc)	Female	11	8.5	128.9	(64.3-230.7)
Female	2	3.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	148	140.7	105.2	(88.9-123.6)
Male	1	2.4	nc	(nc-nc)	Female	129	143.4	89.9	(75.1-106.9)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	18.9	84.6	(48.4-137.5)					
Female	10	18.9	53.0	(25.4-97.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	75	52.9	141.7	(111.4-177.6)	Male	42	25.6	164.0	(118.2-221.7)
Female	23	19.7	116.9	(74.1-175.4)	Female	25	19.2	130.1	(84.2-192.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.1	112.6	(48.5-222.0)	Male	6	7.7	78.1	(28.5-169.9)
Female	5	6.1	81.5	(26.3-190.1)	Female	5	5.9	84.1	(27.1-196.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.4	nc	(nc-nc)	Male	22	23.7	92.8	(58.1-140.5)
Female	166	152.4	108.9	(93.0-126.8)	Female	27	23.6	114.3	(75.3-166.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	5.3	nc	(nc-nc)	Male	12	14.8	80.8	(41.7-141.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	63	73.2	86.1	(66.1-110.1)	Female	19	17.1	111.4	(67.0-173.9)
Female	74	75.7	97.7	(76.7-122.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	14.8	81.2	(41.9-141.9)
Male	14	12.0	116.9	(63.8-196.1)	Female	17	16.7	101.6	(59.2-162.7)
Female	6	3.9	153.8	(56.2-334.8)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	240	175.0	137.1	(120.3-155.6)
Male	4	2.4	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.9	nc	(nc-nc)	Male	13	12.7	102.6	(54.6-175.4)
<u>Kidney and Renal Pelvis</u>					Female	7	8.2	85.0	(34.1-175.2)
Male	17	19.3	88.1	(51.3-141.1)	<u>Testis</u>				
Female	9	13.2	67.9	(31.0-129.0)	Male	1	3.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	7.2	97.4	(39.0-200.7)	Male	1	4.4	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	10	13.1	76.1	(36.4-139.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	14.8	107.8	(61.6-175.0)	Female	29	32.9	88.3	(59.1-126.8)
Female	15	12.2	123.1	(68.8-203.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	715	624.2	114.5	(106.3-123.3)
Male	6	9.2	65.5	(23.9-142.5)	Female	609	580.8	104.9	(96.7-113.5)
Female	3	3.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	104	94.6	109.9	(89.8-133.2)					
Female	95	89.6	106.0	(85.8-129.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;